No Data
No Data
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1
BTIG Maintains Carisma Therapeutics(CARM.US) With Hold Rating
Carisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline Prospects
Express News | Carisma Therapeutics Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $1 From $10
Carisma Therapeutics Cut to In-Line From Outperform by Evercore ISI Group
No Data